TORONTO, ONTARIO-(Marketwired – Sept. 26, 2017) – Interface Biologics Inc. (“IBI”), a privately held, commercial stage company developing innovative material science technologies that save lives and improve patient outcomes, is pleased to announce that Arkis BioSciences® has received 510(k) clearance from U.S. Food and Drug Administration (FDA) for its exclusive CerebroFlo™ EVD Catheter with IBI’s Endexo® technology.Arkis BioSciences signed an agreement to license Endexo technology for Cerebral Spinal Fluid (CSF) shunting, including External Ventricular Drain (EVD) catheters, in March 2015. IBI’s Endexo technology has been proven to be highly effective for reducing catheter occlusions and thrombosis. A recently published study1 of 656 patients from The Ottawa Hospital reported a low rate of Deep Vein Thrombosis (DVT) of only 1.5% for patients using the BioFlo PICC catheter (AngioDynamics Inc). This represents a 56% lower rate of DVTs compared to the average rate of 3.4% reported across 8 studies of 9462 analogous patients using PICCs without Endexo2. In addition, The Ottawa Hospital study reported a low incidence of catheter related blood stream infections (CRBSI) of 0.6% for patients using BioFlo PICCs – an 88.5% lower rate of CRBSI compared to a pooled analysis of 20 studies using other PICCs3. Endexo has significant manufacturing advantages over other antithrombogenic coating or impregnation alternatives and does not change the mechanical or functional properties of the underlying medical device…
Shopping Cart